ResearcherUniversity of Campania "Luigi Vanvitelli"Active in the last 2 years
Michele Caraglia
Matched on ORCID iD 0000-0003-2408-6091; OpenAlex author ID A5073891277. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 2, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 20
2011: 1 paper · 2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper
Papers 6
- Identification of Tissue miRNA Signatures for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16040824↗
- Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ): at the cross-road of pancreatic cancer cell proliferat… First author DOI 10.1016/j.bbcan.2013.11.003↗
- Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Co-author DOI 10.1016/j.ejca.2012.08.019↗
- Combined treatment with PPAR-γ agonists in pancreatic cancer: a glimmer of hope for cancer therapy? First author DOI 10.2174/1568009611313040008↗
- The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells. Last author DOI 10.1016/j.biotechadv.2011.08.001↗
- Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Co-author DOI 10.1038/cddis.2011.36↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Chiara Carmen Miceli · 1 shared paper, 2024 · strength 0.16
- Carlo Caputo · 1 shared paper, 2024 · strength 0.16
- Alessandro Ottaiano · 1 shared paper, 2024 · strength 0.16
- Luca Pompella · 1 shared paper, 2024 · strength 0.16
- Fortunato Ciardiello · 1 shared paper, 2024 · strength 0.16
- Ferdinando De Vita · 1 shared paper, 2024 · strength 0.16
- Donatella Coradduzza · 1 shared paper, 2024 · strength 0.16
- Gabriella Misso · 1 shared paper, 2024 · strength 0.16
- Alessandra Dicitore · 3 shared papers, 2012–2014 · strength 0.11
- Paper Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ): at the cross-r… DOI 10.1016/j.bbcan.2013.11.003↗
- Paper Combined treatment with PPAR-γ agonists in pancreatic cancer: a glimmer of hope for cancer therapy? DOI 10.2174/1568009611313040008↗
- Paper The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pan… DOI 10.1016/j.biotechadv.2011.08.001↗
- Giovanni Vitale · 3 shared papers, 2012–2014 · strength 0.11
- Paper Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ): at the cross-r… DOI 10.1016/j.bbcan.2013.11.003↗
- Paper Combined treatment with PPAR-γ agonists in pancreatic cancer: a glimmer of hope for cancer therapy? DOI 10.2174/1568009611313040008↗
- Paper The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pan… DOI 10.1016/j.biotechadv.2011.08.001↗
- Leo J. Hofland · 2 shared papers, 2012–2013 · strength 0.06
- Paper Combined treatment with PPAR-γ agonists in pancreatic cancer: a glimmer of hope for cancer therapy? DOI 10.2174/1568009611313040008↗
- Paper The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pan… DOI 10.1016/j.biotechadv.2011.08.001↗
- Claudio Arra · 1 shared paper, 2014 · strength 0.04
- Domenico Ciliberto · 1 shared paper, 2013 · strength 0.04
- Pierosandro Tagliaferri · 1 shared paper, 2013 · strength 0.04
- Alfredo Budillon · 1 shared paper, 2012 · strength 0.02
- Elisa Dalla Pozza · 1 shared paper, 2011 · strength 0.02
- Marta Palmieri · 1 shared paper, 2011 · strength 0.02
- Ilaria Dando · 1 shared paper, 2011 · strength 0.02
- Massimo Donadelli · 1 shared paper, 2011 · strength 0.02
- Aldo Scarpa Scarpa · 1 shared paper, 2011 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.